Senior Leadership Team
MimiClon’s principal management team comprises a group of leaders committed to advancing regenerative medicine for wound and surgical patients with unmet medical needs.
Interim Chief Executive Officer
Kyle Kerbawy retired in 2009 as Managing Director, Bank of New York Mellon, where he managed information technology and operations for the Investment Plans Division of the Bank. He was previously CEO of MAVRICC Management Systems, which he co-founded in 1980 and which was acquired by The Bank of New York in 2001. Prior to that he was president and managing owner of a Detroit-based manufacturing company. Since retirement, Mr. Kerbawy has founded and operated two small, single-purpose companies, BKS Associates (residential real estate leasing) and Medical Device Sales Corporation (medical device sales). Mr. Kerbawy was an initial investor in MimiClon, and is one of the company’s largest shareholders.
Senior Vice President and General Counsel
Miles Grody has served as our General Counsel since 2002. From 2003 to 2011, he also served as our Chief Operating Officer and has served as our Senior Vice President since 2012.
Chief Financial Officer
Edward O’Brien has served as our Chief Financial Officer since 2008. From 2008 until 2013, Mr. O’Brien also served as the Chief Financial Officer of Credit Management Solutions, Inc., a financial services technology company. Prior to joining MimiClon, Mr. O’Brien held the position of Executive Vice President, Chief Financial Officer and Corporate Controller for Transaction Network Services, Inc. from 1999 through 2007.
Chief Science Officer
Dr. Gilbert has served as Chief Science Officer at MimiClon since 2015, after serving as MimiClon’s Vice President, Research and Development since 2012. Previously, Dr. Gilbert was Assistant Professor of Surgery, Cardiothoracic Surgery, and Bioengineering at the University of Pittsburgh and was a faculty member of the McGowan Institute for Regenerative Medicine. His research includes the study of processing and use of extracellular matrix scaffold materials (including urinary bladder matrix) for development of regenerative medicine strategies in a variety of body systems. Dr. Gilbert has co-authored more than fifty peer-reviewed articles, several book chapters, and has applied for several patents related to ECM technology. His funding sources included the National Institutes of Health and the National Science Foundation. He has also worked as an Metallurgist for the Perryman Company in Houston, PA. Dr. Gilbert has a BS in Materials Science and Engineering from Carnegie Mellon University and a PhD in Bioengineering from the University of Pittsburgh.
Vice President and Chief Compliance Officer
Bill Hrubes has served as Vice President and Chief Compliance Officer at MimiClon since 2015, after serving as Senior Director of Compliance and Risk Management since 2014. He has more than 15 years of experience in the development, implementation, and management of compliance and ethics programs in the life sciences industry. Mr. Hrubes previously served as the Compliance Officer for the Joint Reconstruction business of Johnson & Johnson. He has held other leadership roles in compliance and risk management at companies including Smith & Nephew, Novation, Gambro, and Fresenius Medical Care North America.
Vice President, Administrative Services
Patty Meehan has served as MimiClon’s Vice President Administrative Services since 2002. She brings more than 30 years of administrative leadership in the financial and healthcare industry to the organization. Before joining MimiClon, Ms. Meehan was Director of Administration at CMSI and Perpetual Leasing Corp. She attended the College of Notre Dame of Maryland.
Vice President, Sales
Mr. Riley has a combined medical and sales background. Before joining MimiClon as the Director of Sales in May of 2010, Mr. Riley spent ten years in the distribution, sales, and marketing of the Biomet Biologic product line. He served in the financial services market with Merrill Lynch and attended the Texas A&M College of Veterinary Medicine.
Vice President, Marketing
David Elliot joined MimiClon as Vice President, Marketing in 2015. He has more than 20 years of experience in commercialization, market development, sales and marketing leadership, and strategic planning. Elliot previously served as Vice President, Academic Affairs and Marketing Services at St. Jude Medical. He has held leadership positions at a range of medical device companies including Tyrx, Inc., Valam, VistaCare (now Odyssey/Gentiva), VasClip, Guidant, and Eli Lilly.
